Advertisement

Pulmonale Hypertonie

  • F. Grimminger
  • D. Walmrath
  • W. Seeger

Zusammenfassung

Die pulmonale Strombahn unterscheidet sich in wesentlichen Punkten von der Strombahn anderer Organe: Das Gefäßsystem der Lunge ist ein Niederdrucksystem. Die arteriellen Drücke und vaskulären Widerstände betragen nur ca. ein Achtel der Werte des großen Kreislaufes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abenhaim L, Moride Y, Brenot F et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609–616.PubMedCrossRefGoogle Scholar
  2. Adnot S, Andrivet P, Chabrier PE et al. (1989) Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. J Clin Invest 83: 986–993.PubMedCrossRefGoogle Scholar
  3. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B (1992) Short and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 102: 1407–1412.PubMedCrossRefGoogle Scholar
  4. Archer SL, Souil E, Dihn-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi E (1998) Molecular identification of the role of voltage-tagged K+ channels, Kv 1.5 and 2.1 in hypoxic pulmonary vasoconstriction and control of resting membrane potentials in rat arterial myocytes. J Clin Invest 10: 1–12.Google Scholar
  5. Archer SL, Kjaballah K, Humbert M, Weir EK, Fartoukh M, Simmonneau G, Dinh-Yuan AT (1998) Nitric oxide deficiency in pulmonary hypertension associated with use of the anorectic agents fenfluramine and dexfenfluramine. Am J Respir Crit Med 157: 594.CrossRefGoogle Scholar
  6. Asherson RA, Khamashta MA, Ordi-Ros J (1989) The primary antiphospholipid syndrome: major clinical and serological features. Medicine 68: 366–374.PubMedCrossRefGoogle Scholar
  7. Bärtsch P, Waber U, Haeberli A, Maggiorni M, Kriemler S, Oelz O, Sträub WP (1987) Enhanced fibrin formation in high altitude pulmonary edema. J Appl Physiol 63: 752–757.PubMedGoogle Scholar
  8. Bärtsch P, Vock P, Maggiorni M et al. (1990) Respiratory symptoms, radiographic and physiologic correlations at high altitude. In: Coates G, Remmers J, Sutton J (eds) Hypoxia: the Adaptations. Decker, Toronto, pp 241–245.Google Scholar
  9. Bärtsch P (1997) High altitude pulmonary edema. Respiration 64: 435–443.PubMedCrossRefGoogle Scholar
  10. Barman SA (1995) Effect of catecholamines on pulmonary circulation at elevated vascular tone. J Appl Physiol 78: 1452–1458.PubMedGoogle Scholar
  11. Barst, RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Int Med 121: 409–415.PubMedCrossRefGoogle Scholar
  12. Barst RJ, Rubin LJ, Long A and the Pulmonary Hypertension Study Group (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334: 296–302.PubMedCrossRefGoogle Scholar
  13. Bartosik I, Eskilsson J, Scheja A, Abesson A (1996) Intermittent iloprost therapy of pulmonary hypertension in scleroderma — a pilot study (Letter). Br J Rheumatol 35: 1187–1188.PubMedCrossRefGoogle Scholar
  14. Bartram SA, Denton CP, du Bois RM, Black CM (1995) Sustained improvement in scleroderma associated pulmonary hypertension following pulsed intravenous prostacyclin therapy. Arthritis Rheum 38: 307.Google Scholar
  15. Cargill RI, Lipworth BJ (1995) Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax 50: 183–185.PubMedCrossRefGoogle Scholar
  16. Carosi JA, Mclntire LV (1993) Effects of cyclicyl strain on the production of vasoactive materials by cultured human and bocine endothelial cells. Eur Respir Rev 3: 598–608.Google Scholar
  17. Chapelier A, Vouhe P, Macchiarini P et al. (1993) Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension. J Thrac Cardiovasc Surg 106: 299–307.Google Scholar
  18. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70–75.PubMedCrossRefGoogle Scholar
  19. Cool SD, Tuder RM, Voelekl NF (1997) Plexiform pulmonary vascular lesions in scleroderma and AIDS: is there a common pathogenesis? Hum Pathol 28: 434–442.PubMedCrossRefGoogle Scholar
  20. Cremona, G, Higgenbottam T (1995) Role of prostacyclin in the treatment of primary pulmonary hypertension. Am J Cardiol 75: 67A–71A.PubMedCrossRefGoogle Scholar
  21. Davis P, Burke G, Reid L (1986) The structure of the wall of the rat intraacinar pulmonary artery: an electron microscopic study of microdissected preparations. Microvasc Res 32: 50–63.CrossRefGoogle Scholar
  22. Dickey BF, Myers AR (1988) Pulmonary manifestations of collagen-vascular diseases, vol 2, part 6,. In: Fishman AP (ed) Pulmonary diseases and disorders. McGraw-Hill, New York, pp 645–663.Google Scholar
  23. Dinh-Xuan AT, Higenbottam TW, Clelland C, Pepke-Zaba J, Cremona G, Wallwork J (1990) Impairment of pulmonary endothelium-dependent relaxations in patients with Eisenmenger’s syndrome. Br J Pharmacol 99: 9–10.PubMedCrossRefGoogle Scholar
  24. Erkan F, Cadvar T (1992) Pulmonary vasculitis in Behcet’s disease. Am Rev Respir Dis 146: 232–239.PubMedCrossRefGoogle Scholar
  25. Gaßner A, Friedrich L, Vagner M, Pichler M (1985) Pulmonale Hypertonie bei chronischer Atemwegsobstruktion. Dtsch Med Wochenschr 110: 247–252.PubMedCrossRefGoogle Scholar
  26. Gaßner A, Friedrich L, Sommer G (1986) Ventrikuläre Rhythmusstörungen bei pulmonaler Hypertonie und chronischer obstruktiver Lungenerkrankung. Dtsch Med Wochenschr 111: 1218–1220.PubMedGoogle Scholar
  27. Giaid A, Yanagisawa M, Langleben D et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739.PubMedCrossRefGoogle Scholar
  28. Giaid A, Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333: 214–221.PubMedCrossRefGoogle Scholar
  29. Grimminger F, Weissmann N, Spriesterbach R, Becker E, Rosseau S, Seeger W (1995) Effects of NADPH Oxidase-inhibitors on hypoxic vasoconstriction in buffer-perfused rabbit lungs. Lung Cell Mol Biol 268: 747–752.Google Scholar
  30. Hackett PH, Rennie D, Levine HD (1976) The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 11: 1149–1154.CrossRefGoogle Scholar
  31. Haufe, MC, Gerzer R, Weil J, Ernst JE, Theisen K (1988) Verapamil impairs secretion of stimulated atrial natriuretic factor in humans. J Am Coll Cardiol 11: 1199–1203.PubMedCrossRefGoogle Scholar
  32. Herget J, Palecek F, Preclik P, Cermakova M, Vizek M, Petrovicka M (1981) Pulmonary hypertension induced by repeated pulmonary inflammation in the rat. J Appl Physiol 51: 755–761.PubMedGoogle Scholar
  33. Herve J, Launay JM, Scrobohaci ML et al. (1995) Increase plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249–254.PubMedCrossRefGoogle Scholar
  34. Herve P, Lebrec D, Brenot F, Simmoneau G, Humbert M, Sitbon O, Duroux P (1998) Pulmonary vascular disorders in portal hypertension. Eur Respir J 11: 1153–1166.PubMedCrossRefGoogle Scholar
  35. Higgenbottam T, Wheeldon D, Wells F, Wallwork J (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1: 1046–1047.CrossRefGoogle Scholar
  36. Higgenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Ccaine N, Wallwork J (1993) The value of prostacyclin (epoprostenol) and heart-lung transplantation for severe pulmonary hypertension. Br Heart J 70: 366–370.CrossRefGoogle Scholar
  37. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Eng J Med 342: 1866–1870.CrossRefGoogle Scholar
  38. Hochstrasser J, Nanzer A, Oelz O (1986) Das Höhenlungenödem in den Schweizer Alpen. Beobachtungen über Inzidenz, Klinik und Verlauf bei 50 Patienten der Jahre 1980–1984. Schweiz Med Wochenschr 116: 866–873.PubMedGoogle Scholar
  39. Humbert M, Monti G, Fartoukh M et al. (1998) Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11: 554–559.PubMedGoogle Scholar
  40. Hyman AL, Kadowitz PJ (1979) Pulmonary vasodilator activity of prostacyclin in the cat. Circ Res 45: 404–409.PubMedCrossRefGoogle Scholar
  41. Ichonese F, Adrie C, Hurford WE, Zapol WM (1995) Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J Appl Physiol 78: 1288–1295.Google Scholar
  42. Janssens SP, Bloch KD, Nong Z, Gerard RD, Zoldhelyi P, Collen D (1996) Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 98: 317–324.PubMedCrossRefGoogle Scholar
  43. Kalra L, Bone MF (1993) Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med 94: 419–423.PubMedCrossRefGoogle Scholar
  44. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ (1995) Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91: 2028–2035.PubMedCrossRefGoogle Scholar
  45. Klinger JR, Petit RA, Warburton RR, Wrenn DS, Arnal F, Hill NS (1993) Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. J Appl Physiol 75: 1615–1623.PubMedGoogle Scholar
  46. Kobayashi T, Koyama S, Kubo K, Fukushima M, Kusama S (1987) Clinical features of patients with high-altitude pulmonary edema in Japan. Chest 92: 814–821.PubMedCrossRefGoogle Scholar
  47. Kshettry VR, Kroshus TJ, Savik K, Hertz MI, Bolman M (1996) Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 110: 704–709.PubMedCrossRefGoogle Scholar
  48. Lee S, Wang WW, Lanzillo JJ, Fanburg BL (1994) Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 266: 46–52.Google Scholar
  49. Lee S, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101: 927–934.PubMedCrossRefGoogle Scholar
  50. Loscalzo J (1995) Nitric oxide and vascular disease. N Engl J Med 333: 251–253.PubMedCrossRefGoogle Scholar
  51. Martin-Duran R, Larman M, Trugeda A et al. (1986) Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization. Am J Cardiol 57: 859–863.PubMedCrossRefGoogle Scholar
  52. Mata J de la, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ (1994) Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 37: 1528–1533.PubMedCrossRefGoogle Scholar
  53. Mathur PN, Powles ACP, Pugsley SO, McEwan MP, Campbell EJM (1981) Effect of digoxin on right ventricular function in severe chronic airflow obstruction. Ann Intern Med 95: 283–288.PubMedCrossRefGoogle Scholar
  54. McDonnell PJ, Toye PA, Hutchins GM (1983) Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 127: 437–441.PubMedGoogle Scholar
  55. McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S (1994) Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 267: 1921–1927.Google Scholar
  56. Moncada S, Vane JR (1979) Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 300: 1142–1147.PubMedCrossRefGoogle Scholar
  57. Moncada S, Palmer R, Higgs E (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109–142.PubMedGoogle Scholar
  58. Moser KM, Auger WR, Fedullo PF (1990) Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 81: 1735–1743.PubMedCrossRefGoogle Scholar
  59. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, W Seeger (1996) Aerosolised prostacyclin and iloprost in primary pulmonary hypertension. Ann Intern Med 124: 820–824.PubMedCrossRefGoogle Scholar
  60. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Höper M, Behr J, Kleber F-X, Seeger W, and the German PPH study group (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH study group. Ann Intern Med 132 (6): 435–443.PubMedCrossRefGoogle Scholar
  61. Ono S, Westcott JY, Voelkel NF (1992) PAF antagonists inhibit pulmonary vascular remodelling induced by hepobaric hypoxia in rats. J Appl Physiol 73: 1084–1092.PubMedGoogle Scholar
  62. Porter TR, Taylor DO, Cycan A, Fields J, Bagley CW, Pandian NG, Mohanty PK (1993) Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 22: 1418–1424.PubMedCrossRefGoogle Scholar
  63. Reeve HL, Archer SL, Weir EK (1997) Ion channels in the pulmonary vasculature. Pulm Pharm Therap 10: 243–252.CrossRefGoogle Scholar
  64. Rich S, Pietra GG, Kieras K, Hart K, Brundage BH (1986) Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 105: 499–502.PubMedCrossRefGoogle Scholar
  65. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81.PubMedCrossRefGoogle Scholar
  66. Rubin LJ, Mendoza J, Hood M et al. (1990) Treatment of pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med 112: 485–491.PubMedCrossRefGoogle Scholar
  67. Rubin LJ (1997) Current Concept — Primary pulmonary hypertension. N Engl J Med 336: 111–116.PubMedCrossRefGoogle Scholar
  68. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG (1988) Long-term treatment of chronic obstructive lung disease by nifedipine: an 18-month haemodynamic study. Europ Resp J 1: 716–720.Google Scholar
  69. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, Guerrero L (1994) Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89: 1733–1744.PubMedCrossRefGoogle Scholar
  70. Singh I, Kapila CC, Khanna PK, Nanda RB, Rao BDP (1965) High-altitude pulmonary oedema. Lancet i: 229–234.CrossRefGoogle Scholar
  71. Speich R, Jenni R, Opravil M, Pfab M, Russi EW (1991) Primary pulmonary hypertension in HIV infection. Chest 100: 1268–1271.PubMedCrossRefGoogle Scholar
  72. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275–285.PubMedGoogle Scholar
  73. Tuxen DV, Powles AC, Mathur PN, Pugsley SO, Campbell EJ (1984) Detrimental effects of hydralazine in patients with chronic airflow obstruction and pulmonary hypertension. A combined hemodynamic and radionuclide study. Am Rev Respir Dis 129: 388–395.PubMedGoogle Scholar
  74. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM (1998) Primary pulmonary hypertension between inflammation and cancer. Chest 114: 225–230.CrossRefGoogle Scholar
  75. Wagenvoort CA (1960) Vasoconstriction and medical hypertrophy in pulmonary hypertension. Circulation 22: 535–546.PubMedCrossRefGoogle Scholar
  76. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W (1993) Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS). Lancet 342: 961–962.PubMedCrossRefGoogle Scholar
  77. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W (1995) Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 151: 724–730.PubMedGoogle Scholar
  78. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG et al. (1994) Endothelin in human congestive heart failure. Circulation 89: 1580–1586.PubMedCrossRefGoogle Scholar
  79. Winter RJ, Zhao L, Krausz T, Hughes JM (1991) Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Am Rev Respir Dis 144: 1342–1346.PubMedCrossRefGoogle Scholar
  80. Wood P (1958) Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 20: 557–570.PubMedCrossRefGoogle Scholar
  81. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF (1998) 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 157: 219–229.PubMedCrossRefGoogle Scholar
  82. Youngson C, Nurse C, Yeger H, Cutz E (1993) Oxygen sensing in airway chemoreceptors. Nature 365: 153–155.PubMedCrossRefGoogle Scholar
  83. Yuan JX, Aldinger AM, Juhaszowa M et al. (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 14: 1400–1406.CrossRefGoogle Scholar
  84. Zapol W, Rimar S, Gillis N, Marietta M, Boslaw C (1994) Nitric oxide and the lung. Am J Respir Crit Care Med 149: 1375–1380.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • F. Grimminger
  • D. Walmrath
  • W. Seeger

There are no affiliations available

Personalised recommendations